|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquired_by
|
gptkb:Roche
|
|
gptkbp:ceo
|
gptkb:Alexander_Hardy
|
|
gptkbp:clinical_trial
|
ongoing
completed
FDA approved
investigational new drug applications
phases 1-3
|
|
gptkbp:community_involvement
|
gptkb:Philanthropy
educational initiatives
volunteer programs
environmental sustainability efforts
healthcare access programs
|
|
gptkbp:employees
|
approximately 13,000
|
|
gptkbp:founded
|
gptkb:1976
|
|
gptkbp:founder
|
gptkb:Robert_E._Swanson
gptkb:Herbert_Boyer
|
|
gptkbp:headcount
|
approximately 13,000
|
|
gptkbp:headquarters
|
gptkb:South_San_Francisco,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Genentech, Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:location
|
gptkb:California
|
|
gptkbp:notable_achievement
|
developed the first monoclonal antibody therapy
pioneered the field of biotechnology
first company to produce a recombinant human insulin
|
|
gptkbp:part_of
|
gptkb:Roche_Group
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Biogen
gptkb:Amgen
gptkb:Novartis
|
|
gptkbp:products
|
gptkb:Avastin
gptkb:Herceptin
gptkb:Lucentis
gptkb:Rituxan
gptkb:Xolair
|
|
gptkbp:research_focus
|
gptkb:Oncology
cardiology
neuroscience
immunology
ophthalmology
|
|
gptkbp:revenue
|
$26.1 billion (2020)
|
|
gptkbp:stock_symbol
|
gptkb:DNA
|
|
gptkbp:subsidiary
|
gptkb:Roche_Holding_AG
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.gene.com
|
|
gptkbp:bfsParent
|
gptkb:founding_Genentech
|
|
gptkbp:bfsLayer
|
6
|